H.C. Wainwright raised the firm’s price target on Argenx to $504 from $490 and keeps a Buy rating on the shares following the research and development day. The analyst believes Argenx effectively addressed questions about short, medium and long-term growth. The data for empasiprubart has been “impressive” and gives confidence that the company already has a potential second blockbuster in its portfolio, moving beyond a single-product story, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Zai Lab, Argenx announce China NMPA approval for efgartigimod alfa injection
- argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
- Argenx to host research and development day
- Argenx price target raised to $533 from $478 at Evercore ISI
- Lexeo Therapeutics appoints Tim Van Hauwermeiren to board of directors